公开(公告)号：US10603314B2

公开(公告)日：2020-03-31

申请号：US11883474

申请日：2006-02-02

申请人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Sridhar Krishna Rabindran

发明人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Sridhar Krishna Rabindran

IPC分类号： A61K31/4709 ,  A61K31/4706 ,  A61K31/17 ,  A61K38/17

摘要： The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

公开(公告)号：US20100087482A1

公开(公告)日：2010-04-08

申请号：US11883474

申请日：2006-02-02

申请人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Krishna Rabindran

发明人： Daniel A. Haber ,  Daphne Winifred Bell ,  Jeffrey E. Settleman ,  Raffaella Sordella ,  Nadia G. Godin-Heymann ,  Eunice L. Kwak ,  Krishna Rabindran

IPC分类号： A61K31/4706 ,  A61P35/00 ,  A61K31/4709

CPC分类号： A61K31/4709 ,  A61K31/4706 ,  A61K38/17

摘要： The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

摘要翻译： 本发明涉及用于治疗吉非替尼和/或厄洛替尼耐药性癌症的方法。 在用吉非替尼和/或厄洛替尼治疗后，监测癌症患者的癌症发展。 癌症的进展表明癌症对吉非替尼和/或厄洛替尼具有抗性。 一旦注意到癌的进展，给予受试者包含不可逆表皮生长因子受体（EGFR）抑制剂的药物组合物。 在优选的实施方案中，不可逆EGFR抑制剂是EKB-569，HKI-272和HKI-357。

公开(公告)号：US08105769B2

公开(公告)日：2012-01-31

申请号：US11894135

申请日：2007-08-20

申请人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

发明人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/485 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/74 ,  G01N2333/485 ,  G01N2800/52

摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

摘要翻译： 本发明涉及确定癌症对表皮生长因子受体（EGFR）治疗的反应性的方法。 在优选的实施方案中，erbB1基因的激酶结构域中存在至少一个方差赋予对酪氨酸激酶抑制剂吉非替尼的敏感性。 因此，这些突变的诊断测定将允许对最可能对药物作出反应的那些患者施用吉非替尼，厄洛替尼和其他酪氨酸激酶抑制剂。

公开(公告)号：US07964349B2

公开(公告)日：2011-06-21

申请号：US11894159

申请日：2007-08-20

申请人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

发明人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/485 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/74 ,  G01N2333/485 ,  G01N2800/52

摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

摘要翻译： 本发明涉及确定癌症对表皮生长因子受体（EGFR）治疗的反应性的方法。 在优选的实施方案中，erbB1基因的激酶结构域中存在至少一个方差赋予对酪氨酸激酶抑制剂吉非替尼的敏感性。 因此，这些突变的诊断测定将允许对最可能对药物作出反应的那些患者施用吉非替尼，厄洛替尼和其他酪氨酸激酶抑制剂。

公开(公告)号：US07294468B2

公开(公告)日：2007-11-13

申请号：US11294621

申请日：2005-12-05

申请人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnson ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

发明人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnson ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/485 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/74 ,  G01N2333/485 ,  G01N2800/52

摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

摘要翻译： 本发明涉及确定癌症对表皮生长因子受体（EGFR）治疗的反应性的方法。 在优选的实施方案中，erbB1基因的激酶结构域中存在至少一个方差赋予对酪氨酸激酶抑制剂吉非替尼的敏感性。 因此，这些突变的诊断测定将允许对最可能对药物作出反应的那些患者施用吉非替尼，厄洛替尼和其他酪氨酸激酶抑制剂。

公开(公告)号：US08465916B2

公开(公告)日：2013-06-18

申请号：US11894160

申请日：2007-08-20

申请人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

发明人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/485 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/74 ,  G01N2333/485 ,  G01N2800/52

摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

摘要翻译： 本发明涉及确定癌症对表皮生长因子受体（EGFR）治疗的反应性的方法。 在优选的实施方案中，erbB1基因的激酶结构域中存在至少一个方差赋予对酪氨酸激酶抑制剂吉非替尼的敏感性。 因此，这些突变的诊断测定将允许对最可能对药物作出反应的那些患者施用吉非替尼，厄洛替尼和其他酪氨酸激酶抑制剂。

公开(公告)号：US20080234264A1

公开(公告)日：2008-09-25

申请号：US11894160

申请日：2007-08-20

申请人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

发明人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

IPC分类号： A61K31/5377 ,  C12Q1/68 ,  A61K31/517 ,  C12N15/12 ,  C07K14/47 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  C12Q1/485 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/74 ,  G01N2333/485 ,  G01N2800/52

摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

摘要翻译： 本发明涉及确定癌症对表皮生长因子受体（EGFR）治疗的反应性的方法。 在优选的实施方案中，erbB1基因的激酶结构域中存在至少一个方差赋予对酪氨酸激酶抑制剂吉非替尼的敏感性。 因此，这些突变的诊断测定将允许对最可能对药物作出反应的那些患者施用吉非替尼，厄洛替尼和其他酪氨酸激酶抑制剂。

公开(公告)号：US20080207615A1

公开(公告)日：2008-08-28

申请号：US11894159

申请日：2007-08-20

申请人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

发明人： Daphne Winifred Bell ,  Daniel A. Haber ,  Pasi Antero Janne ,  Bruce E. Johnston ,  Thomas J. Lynch ,  Matthew Meyerson ,  Juan Guillermo Paez ,  William R. Sellers ,  Jeffrey E. Settleman ,  Raffaella Sordella

IPC分类号： A61K31/5377 ,  C12Q1/68 ,  A61K31/517 ,  C12N15/12 ,  C07K14/47 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  C12Q1/485 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/574 ,  G01N33/74 ,  G01N2333/485 ,  G01N2800/52

摘要： The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.